Display Settings:

Format

Send to:

Choose Destination
    Cancer. 2004 Dec 1;101(11):2641-9.

    The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor.

    Source

    Department of Radiation Oncology, Emory Clinic/Emory University, Atlanta, Georgia, USA.

    Abstract

    BACKGROUND:

    The authors performed a comprehensive review of the efficacy of fluorodeoxyglucose positron emission tomography (FDG-PET) in the detection of primary tumors in patients with cervical metastases from unknown primary tumors.

    METHODS:

    Sixteen studies (involving a total of 302 patients) published between 1994 and 2003 were reviewed. These studies evaluated the role of FDG-PET in the detection of unknown primary tumors after conventional workup. In all studies, conventional workup included either panendoscopy or computed tomographic/magnetic resonance imaging, and in 10 of 16 studies, both of these diagnostic techniques were performed before diagnosis.

    RESULTS:

    The overall sensitivity, specificity, and accuracy rates of FDG-PET in detecting unknown primary tumors were 88.3%, 74.9%, and 78.8%, respectively. Furthermore, FDG-PET detected 24.5% of tumors that were not apparent after conventional workup. FDG-PET imaging also led to the detection of previously unrecognized metastases in 27.1% of patients (regional, 15.9%; distant, 11.2%). FDG-PET had notably low specificity and a high false-positive rate (39.3%) in the tonsils. In contrast, the false-positive rates for FDG-PET of the base of tongue and hypopharynx were only 21.4% and 8.3%, respectively. FDG-PET exhibited decreased sensitivity to tumors in the base of tongue (81.5%). The sensitivity of this technique at other sites was 90.5%.

    CONCLUSIONS:

    FDG-PET detected primary tumors that went undetected by other modalities in approximately 25% of cases and was sensitive in the detection of previously unrecognized regional or distant metastases in 27% of cases. FDG-PET had low specificity for tonsillar tumors and low sensitivity for base-of-tongue malignancies.

    (c) 2004 American Cancer Society

    PMID:
    15517576
    [PubMed - indexed for MEDLINE]
    Free full text

      Supplemental Content

      Icon for John Wiley & Sons, Inc.

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk